Accéder au contenu
Merck

Thyroid hormone and thyromimetics inhibit myelin and axonal degeneration and oligodendrocyte loss in EAE.

Journal of neuroimmunology (2021-01-11)
P Chaudhary, G H Marracci, E Calkins, E Pocius, A L Bensen, T S Scanlan, B Emery, D N Bourdette
RÉSUMÉ

We have previously demonstrated that thyromimetics stimulate oligodendrocyte precursor cell differentiation and promote remyelination in murine demyelination models. We investigated whether a thyroid receptor-beta selective thyromimetic, sobetirome (Sob), and its CNS-targeted prodrug, Sob-AM2, could prevent myelin and axonal degeneration in experimental autoimmune encephalomyelitis (EAE). Compared to controls, EAE mice receiving triiodothyronine (T3, 0.4 mg/kg), Sob (5 mg/kg) or Sob-AM2 (5 mg/kg) had reduced clinical disease and, within the spinal cord, less tissue damage, more normally myelinated axons, fewer degenerating axons and more oligodendrocytes. T3 and Sob also protected cultured oligodendrocytes against cell death. Thyromimetics thus might protect against oligodendrocyte death, demyelination and axonal degeneration as well as stimulate remyelination in multiple sclerosis.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Anticorps anti-Aspa/Nur7, from rabbit, purified by affinity chromatography
Sigma-Aldrich
Sob-AM2, ≥98% (HPLC)
Sigma-Aldrich
Anticorps anti-CNPase, clone 11-5B, clone 11-5B, Chemicon®, from mouse